title: Reduced sensitivity to pirenzepine-induced blockade of growth hormone responses to arginine, exercise, and growth hormone-releasing hormone in type I diabetic subjects.
abstract: The present study was performed to establish whether the mechanism by which the cholinergic system influences growth hormone (GH) release was altered in type I diabetic patients. Therefore, we investigated in a dose-response fashion the inhibitory effect of the muscarinic cholinergic receptor antagonist pirenzepine on the GH responses to arginine infusion (30 g infused intravenously (IV) in 30 minutes), exercise (bicycle ergometer test at an intensity of 75 W for 30 minutes), or 1-44 GH-releasing hormone (GHRH) (1 microgram/kg in an IV bolus). In a preliminary study, IV injection of 17.5 mg pirenzepine failed to produce modification in the GH response to arginine infusion in both diabetic (N = 4) and normal subjects (N = 4), and to exercise (diabetics, N = 4; normals, N = 4). Therefore, other subjects were tested without and with 20, 25, and 30 mg pirenzepine during arginine (diabetics, N = 7; normals, N = 7) or exercise (diabetics, N = 7; normals, N = 7) tests. Each subject was tested four times. Diabetic patients presented higher GH responses to stimulation with arginine or exercise than normal controls. In both groups, pirenzepine administered at doses ranging from 20 to 30 mg produced a dose-related inhibition of the GH response to arginine and exercise, which was almost complete when 30 mg pirenzepine was administered. However, the percent inhibition produced by 20 or 25 mg pirenzepine in the arginine test and by 20 mg in the exercise test was significantly lower in the diabetic patients than in the normal controls.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: University Clinic of Internal Medicine, School of Medicine, University of Parma, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Coiro
authors.forename: M
authors.initials: M
authors.lastname: Passeri
authors.forename: E
authors.initials: E
authors.lastname: Gardini
authors.forename: L
authors.initials: L
authors.lastname: Capretti
authors.forename: G
authors.initials: G
authors.lastname: Speroni
authors.forename: C
authors.initials: C
authors.lastname: Davoli
authors.forename: M L
authors.initials: ML
authors.lastname: Maffei
authors.forename: F
authors.initials: F
authors.lastname: Fagnoni
authors.forename: L
authors.initials: L
authors.lastname: Bianconi
authors.forename: R
authors.initials: R
authors.lastname: Volpi
mesh_terms: D000293:Adolescent; D000328:Adult; D001120:Arginine; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D015444:Exercise; D005934:Glucagon / Q000097:blood; D013006:Growth Hormone / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D007700:Kinetics; D018727:Muscarinic Antagonists; D010890:Pirenzepine / Q000494:pharmacology*; D011976:Receptors, Muscarinic / Q000502:physiology*
chemical_list: D001786:Blood Glucose; D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic; D010890:Pirenzepine; D013006:Growth Hormone; D005934:Glucagon; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine